Biomarkers to Detect Endocrine Therapy Resistance

PHASE2RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Metastatic CancerBreast CancerLobular Breast Carcinoma
Interventions
DRUG

18F-fluorofuranylnorprogesterone

The dose of the investigational imaging agent, FFNP, is approximately 7 millicurie (mCi) (259 megabecquerels (MBq)), IV slow infusion over approximately two minutes followed by saline flush.

DEVICE

Liquid Biopsy

20ml of whole blood will be collected into two Ethylenediaminetetraacetic acid (EDTA) tubes at each timepoint, CTCs are isolated using the microfluidic Versatile Exclusion-based Rare Sample Analysis (VERSA) platform that integrates CTC capture with RNA extraction on a single chip using Exclusion-Based Sample Preparation (ESP) technology

DEVICE

Positron Emission Tomography/Computed Tomography

FFNP drug in combination with PET/CT scans to image participant

Trial Locations (1)

53792

RECRUITING

UW Carbone Cancer Center, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER